

DOSING FOR 3 INDICATIONS

Inflammation is an important component in the pathogenesis of atopic dermatitis, asthma, and CRSwNP

INDICATIONS



ATOPIC DERMATITIS

Treatment of patients (6+ years) with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids



ASTHMA

As add-on maintenance treatment for patients (12+ years) with moderate-to-severe asthma with an eosinophilic phenotype or with oral corticosteroid dependent asthma

Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.



CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (CRSwNP)

As an add-on maintenance treatment in adult patients (18+ years) with inadequately controlled CRSwNP


IMPORTANT SAFETY INFORMATION

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

Please see additional Important Safety Information throughout and click [here](#) for full Prescribing Information.

DOSING FOR UNCONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS

ADULTS (18+ years)



Sample prescription for 300 mg dose Q2W

Rx DUPIXENT® (dupilumab)
300 mg/2 mL PRE-FILLED SYRINGE 2-PACK

INITIAL DOSE: # OF 2-PACKS
600 mg QTY: 1

Sig: 2 injections subcutaneously on Day 1
(BOTH PRE-FILLED SYRINGES OF THE 2-PACK)

MAINTENANCE DOSE: # OF 2-PACKS REFILLS:
300 mg QTY: 1

Sig: 1 injection 2 weeks after on Day 15
(1ST PRE-FILLED SYRINGE OF THE 2-PACK)

and 1 injection 2 weeks after on Day 29
(2ND PRE-FILLED SYRINGE OF THE 2-PACK)
and every 2 weeks thereafter

1 refill provides 4 weeks of maintenance therapy.

Q2W, once every 2 weeks.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including generalized urticaria, rash, erythema nodosum, anaphylaxis and serum sickness or serum sickness-like reactions, were reported in <1% of subjects who received DUPIXENT in clinical trials. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.


Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT with conjunctivitis being the most frequently reported eye disorder in these patients. Conjunctivitis also occurred more frequently in chronic rhinosinusitis with nasal polyposis subjects who received DUPIXENT. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.

Eosinophilic Conditions: Patients being treated for asthma may present with serious systemic eosinophilia sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis (EGPA), conditions which are often treated with systemic corticosteroid therapy.

Please see additional Important Safety Information throughout and click [here](#) for full Prescribing Information.

PEDIATRIC PATIENTS (6-17 years)

Weight-tiered dosage regimen^a



^a15 kg is equal to 33 lb; 30 kg is equal to 66 lb; 60 kg is equal to 132 lb.

Sample prescription for 300 mg dose Q4W

Rx DUPIXENT® (dupilumab)
300 mg/2 mL PRE-FILLED SYRINGE 2-PACK

INITIAL DOSE: # OF 2-PACKS
600 mg QTY: 1

Sig: 2 injections subcutaneously on Day 1
(BOTH PRE-FILLED SYRINGES OF THE 2-PACK)

MAINTENANCE DOSE: # OF 2-PACKS REFILLS:
300 mg QTY: 1

Sig: 1 injection 4 weeks after on Day 29
(1ST PRE-FILLED SYRINGE OF THE 2-PACK)
and 1 injection 4 weeks after on Day 58
(2ND PRE-FILLED SYRINGE OF THE 2-PACK)
and every 4 weeks thereafter

1 refill provides 8 weeks of maintenance therapy.

Q4W, once every 4 weeks.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

Eosinophilic Conditions (cont'd)


These events may be associated with the reduction of oral corticosteroid therapy. Physicians should be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients with eosinophilia. Cases of eosinophilic pneumonia were reported in adult patients who participated in the asthma development program and cases of vasculitis consistent with EGPA have been reported with DUPIXENT in adult patients who participated in the asthma development program as well as in adult patients with co-morbid asthma in the CRSwNP development program. A causal association between DUPIXENT and these conditions has not been established.

DUPIXENT®
(dupilumab)

DOSING FOR MODERATE-TO-SEVERE ASTHMA

ADULTS/ADOLESCENTS (12+ years)

Moderate-to-severe asthma with an eosinophilic phenotype



OCS-dependent asthma or patients with comorbid moderate-to-severe atopic dermatitis for which DUPIXENT is indicated

- Initial dose is 600 mg (two 300 mg pre-filled syringes) followed by every-2-week dosing of a 300 mg pre-filled syringe

Sample prescription for 300 mg dose Q2W

Rx DUPIXENT® (dupilumab)
300 mg/2 mL PRE-FILLED SYRINGE 2-PACK

INITIAL DOSE: # OF 2-PACKS
600 mg QTY: 1

Sig: 2 injections subcutaneously on Day 1
(BOTH PRE-FILLED SYRINGES OF THE 2-PACK)

MAINTENANCE DOSE: # OF 2-PACKS REFILLS:
300 mg QTY: 1

Sig: 1 injection 2 weeks after on Day 15
(1ST PRE-FILLED SYRINGE OF THE 2-PACK)

and 1 injection 2 weeks after on Day 29
(2ND PRE-FILLED SYRINGE OF THE 2-PACK)
and every 2 weeks thereafter

1 refill provides 4 weeks of maintenance therapy.

OCS, oral corticosteroid.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

Acute Asthma Symptoms or Deteriorating Disease: Do not use DUPIXENT to treat acute asthma symptoms, acute exacerbations, acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of DUPIXENT.

Please see additional Important Safety Information throughout and click [here](#) for full Prescribing Information.

DOSING FOR INADEQUATELY CONTROLLED CRSwNP

ADULTS (18+ years)

Inadequately controlled CRSwNP



Sample prescription for 300 mg dose Q2W (no loading dose)

Rx DUPIXENT® (dupilumab)
300 mg/2 mL PRE-FILLED SYRINGE 2-PACK

MAINTENANCE DOSE: # OF 2-PACKS REFILLS:
300 mg QTY: 1

Sig: 1 injection subcutaneously on Day 1
(1ST PRE-FILLED SYRINGE OF THE 2-PACK)

and 1 injection 2 weeks after on Day 15
(2ND PRE-FILLED SYRINGE OF THE 2-PACK)
and every 2 weeks thereafter

1 refill provides 4 weeks of maintenance therapy.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (cont'd)

Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation with DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Patients with Co-Morbid Asthma: Advise patients with atopic dermatitis or CRSwNP who have co-morbid asthma not to adjust or stop their asthma treatments without consultation with their physician.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

DUPIXENT®
(dupilumab)

DUPIXENT OFFERS AT-HOME OR IN-OFFICE ADMINISTRATION OPTIONS

How to take DUPIXENT

- DUPIXENT is intended for use under the guidance of a healthcare provider
- A patient may self-inject DUPIXENT after receiving training in subcutaneous injection technique using the pre-filled syringe
 - In adolescents 12 years of age and older, it is recommended that DUPIXENT be administered by or under the supervision of an adult
 - DUPIXENT pre-filled syringe should be given by a caregiver in children 6 to 11 years of age
 - Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use according to the Instructions for Use
- DUPIXENT can be administered in the office under the guidance of a healthcare provider if the patient is not an appropriate candidate for self-administration
- If a dose is missed, administer the injection within 7 days from the missed dose and then resume the patient's original schedule. If the missed dose is not administered within 7 days, wait until the next dose on the original schedule

Specific to moderate-to-severe atopic dermatitis

- DUPIXENT can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used, but should be reserved for problem areas only, such as the face, neck, and intertriginous and genital areas
- There is no requirement for initial lab testing or ongoing lab monitoring, according to the DUPIXENT Prescribing Information

IMPORTANT SAFETY INFORMATION


ADVERSE REACTIONS:

- **Atopic dermatitis:** The most common adverse reactions (incidence $\geq 1\%$ at Week 16) in adult patients are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. The safety profile in children and adolescents through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT in adolescents and children observed through Week 52 was consistent with that seen in adults with atopic dermatitis.
- **Asthma:** The most common adverse reactions (incidence $\geq 1\%$) are injection site reactions, oropharyngeal pain, and eosinophilia.
- **Chronic rhinosinusitis with nasal polyposis:** The most common adverse reactions (incidence $\geq 1\%$) are injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis.

Please see additional Important Safety Information throughout and click [here](#) for full Prescribing Information.

Administer at different injection sites

- *Atopic dermatitis and asthma patients:* For the initial dose, administer each of the 2 injections at different injection sites
- Administer the subcutaneous injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel
- The upper arm can also be used if a caregiver administers the injection
- Rotate the injection site with each injection. DO NOT inject DUPIXENT into skin that is tender, damaged, bruised, or scarred



How DUPIXENT is supplied

DUPIXENT is available in cartons containing 2 pre-filled syringes with needle shield. The pre-filled syringe is designed to deliver 300 mg of DUPIXENT in a 2 mL solution or 200 mg dose in a 1.14 mL solution.

DUPIXENT prescriptions can be filled at select retail pharmacies or through specialty pharmacies, which can ship medication directly to patients.



IMPORTANT SAFETY INFORMATION

DRUG INTERACTIONS: Avoid use of live vaccines in patients treated with DUPIXENT.

USE IN SPECIFIC POPULATIONS

- **Pregnancy:** Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.

DUPIXENT
(dupilumab)

DUPIXENT MyWay® PROVIDES ELIGIBLE PATIENTS WITH SUPPORT

A completed *DUPIXENT MyWay* Enrollment Form triggers these support resources



Nursing Support

Nursing support

- Nurse educators take a patient-centric approach to providing tools, resources, and education that supports patients with starting and staying on DUPIXENT
- Supplemental injection training in addition to the training you provide to your patients—either over the phone, virtually, or in person



Coverage Support

Provides assistance navigating the insurance process

- Conducts benefits investigations and provides education about the prior authorization process
- Educates staff about appropriate actions needed to appeal any coverage denial^a



Patient Access Support

- Eligible patients covered by commercial health insurance may pay as little as a \$0 copay per fill of DUPIXENT
- THIS IS NOT INSURANCE. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, Veterans Affairs, Department of Defense, TRICARE, or other federal or state programs. Eligible patients subject to program restrictions. Program has an annual maximum of \$13,000

^aApproval is not guaranteed. Appealing the health plan's denial does not always result in approval of DUPIXENT.

■ Visit **DUPIXENTHCP.COM** for more information

IMPORTANT SAFETY INFORMATION

USE IN SPECIFIC POPULATIONS (cont'd)

- **Lactation:** There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

DUPIXENT® and *DUPIXENT MyWay*® are registered trademarks of Sanofi Biotechnology.

Reference: DUPIXENT Prescribing Information.

Please see additional Important Safety Information throughout and click [here](#) for full Prescribing Information.

DUPIXENT® 
(dupilumab)

SANOFI GENZYME 

REGENERON